New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 7, 2014
05:59 EDTARIA, PLUGStocks with implied volatility below IV index mean; PLUG ARIA
Stocks with implied volatility movement; Plug Power (PLUG) 145, ARIAD (ARIA) 105 according to iVolatility.
News For PLUG;ARIA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 4, 2015
16:56 EDTPLUGAxane reports 5.64% stake in Plug Power
Subscribe for More Information
09:16 EDTPLUGOn The Fly: Pre-market Movers
Subscribe for More Information
07:34 EDTARIAUBS to hold a symposium
Subscribe for More Information
August 3, 2015
19:01 EDTPLUGOn The Fly: After Hours Movers
Subscribe for More Information
16:37 EDTPLUGPlug Power files to sell 7.9M shares for selling stockholders
Subscribe for More Information
July 29, 2015
07:47 EDTARIAARIAD to receive $200M through syntehtic-royalty financing with PDL BioPharma
Subscribe for More Information
07:43 EDTARIAARIAD to receive up to $200M through Iclusig synthetic-royalty financing with PDL BioPharma
ARIAD Pharmaceuticals (ARIA) announced that it will receive $100 million in cash – $50 million upon deal execution late yesterday and an additional $50 million in one year – through a synthetic-royalty financing from PDL BioPharma (PDLI) in exchange for paying PDL a mid-single-digit royalty on future sales of Iclusig until PDL receives a fixed internal rate of return. ARIAD also has an option, in its discretion, to receive up to an additional $100 million at any time between 6 and 12 months from the date of the agreement, in one or two tranches on comparable terms. ARIAD intends to use the base funds to conduct a front-line trial of brigatinib, its investigational ALK inhibitor, in patients with non-small cell lung cancer and to support brigatinib commercial readiness, as well as to continue its ongoing Iclusig initiatives. ARIAD is on track to complete enrollment in the pivotal ALTA trial of brigatinib in third quarter 2015, to file for approval in the U.S. next year, and subject to regulatory approval, to launch brigatinib by early 2017. Brigatinib has Breakthrough Designation from the U.S. Food and Drug Administration. “This financing allows us to accelerate initiation of the front-line trial of brigatinib and to ensure launch readiness as early as possible, while retaining strategic flexibility with respect to partnering and long-term commercialization of brigatinib,” said Harvey J. Berger, M.D., chairman and CEO of ARIAD. “We are confident based on the latest clinical data on brigatinib and other ALK‐inhibitors, that brigatinib may be an important new cancer medicine for patients with ALK+ lung cancer. With the funding provided by this royalty transaction, we expect to start the front-line trial by early next year, ahead of our expected filing for initial marketing approval of brigatinib in patients with refractory ALK+ NSCLC.”
July 28, 2015
10:00 EDTPLUGOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:22 EDTPLUGPlug Power initiated with a Buy at Craig-Hallum
Target $3.50.
July 27, 2015
07:08 EDTPLUGPlug Power acquires full control of HyPulsion JV for $11.47M in stock
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use